Solutions
Circulating Tumor Cell Clinical Research

RareCyte® enables practical deployment of circulating tumor cell-based liquid biopsy with instrumentation and consumables that provide an exquisitely sensitive, accurate, reproducible, and transparent workflow from blood collection to single-cell isolation.

  • Unbiased, reproducible, highly sensitive, and specific circulating tumor cell detection
  • Scalable, high-capacity platform with workflow breakpoints, including slide banking, that enable multi-site execution
  • Deploy through our global contract research organization (CRO) network or in your own lab
  • Utilize cancer-specific panels or Developer panels for circulating tumor cell biomarker analysis
  • Custom assay and companion diagnostics co-development through our Pharma Programs 

TALK TO AN EXPERT



RareCyte panels for liquid biopsy analysis include markers used for circulating tumor cell identification and biomarker exploration. Circulating tumor cells are identified as nucleated cells that express CK/EpCAM but not CD45. The breast assay used the RarePlex HER2/ER CTC Panel Kit and the prostate assay used the ARv7 CTC Panel Kit and a Developer Kit for AR. With Developer technology, you can customize your panel with up to two of your own biomarkers.
RarePlex® Assays: Design and Analytical Validation
Presented by Dr. Tad George, Sr. VP of Biology R&D
RarePlex Assays are sensitive, specific, and reproducible assays for CTC detection and biomarker expression. Gain insight into the principles RareCyte applies to its assay design and validation process in this 11 minute video.
CyteFinder® HT with 80-slide capacity for clinical research.
Three-day blood stability and option to bank slides before staining enables practical multi-site workflow for clinical research.
Five-cell circulating tumor cell cluster expressing drug target from a clinical research study participant. Cytokeratin (red) / EpCAM (magenta) / Drug target (green) / CD45 (yellow) / nuclei (blue)
RarePlex® Panel and Developer Assays for CTC enumeration and characterization
Presented by Arturo Ramirez, Ph.D., Director of Oncology R&D
This 7 minute overview of RarePlex Panel Kits and Developer technology highlights available circulating tumor cell assays from RareCyte and presents an introduction to our assay design and validation.
Bank AccuCyte slides in freezer prior to staining.

WEBINAR: Analytical Validation of CTC Enumeration using the RareCyte Platform and Implementation in a Global Clinical Trial

This webinar describes how the RareCyte platform for CTC analysis was validated in the Clinical Diagnostics Lab (CAP accredited CLIA Lab) at Eli Lilly. The results met the requirements of the Clinical Drug Study Team and the RareCyte platform was added to a global clinical trial for further evaluation in collaboration with a CRO. A short presentation on RareCyte CTC assays for enumeration, multi-biomarker analysis, and custom assay development capabilities follows.

Speakers:
Jeff Fill, MBA, MT(ASCP), Senior Director, Diagnostic and Experimental Pathology, Lilly Research Laboratories, Eli Lilly and Company
Arturo Ramirez, PhD, Director of Oncology, RareCyte, Inc.


VIEW THE WEBINAR